Labeling every one as "lesbian" is like labeling every fruit as "apple"
I have a question:
Is everyone who says "we should not label orange as apple", enemy of orange?
Do everyone who says "we should not use the word "cat" for "dog", discriminating against cats?
So why do some of us, think that people who say "men can not use lesbian label for themselves" , are enemy of men ?
Why do we think that assigning the word lesbian to women and female-aligned non-binaries, means enmity with those who are not women or fem-aligned?
Please understand that the use of words and labels for certain things is to prevent words get meaningless, not to discriminate against those who are excluded from these words.
I believe that the term lesbian should be used only for women or fem-aligned enbies, because otherwise words and topics become meaningless, and I also believe that insisting on including men in the identity of lesbians is a form of heterosexualization of queer women, although some ppl think it is the opposite. According to many, this issue will de-radicalize the lesbian community and not radicalize the lesbian identity.
Listen, this is my perspective on the "What is a woman" thing.
If I look at a tree & someone were to ask me what it is, I'd say it was a tree. If they then asked me what a tree was, I'd then say that "a tree is a type of flora of the arboreal persuasion" or something to that affect.
Does this make me shrubphobic or flowerphobic? What about vinephobic?
No? Exactly! It just means that I'm intelligent enough to be able to pick up context clues, put them together, & identify what it is in front of me. Just because I am able to properly lable something for what it is doesn't mean that I'm somehow afraid of or hate something else!
That's psychotic! Deranged even!
Listen, we humans are sexually dimorphic, just like any other mammal on this planet. This means that there are very apparent, biological differences between males & females.
If you're asking me to ignore this basic fact of science, then I have full clearance to ignore any other.
It always tickles me how the left insist on getting everyone to 'follow the science' with abortions, but when it comes to gender identity, they completely ignore one of the most basic of basic scientific facts in the universe. Females can have babies & males can not.
That is how reproduction works. Without it, which seems to be where all this shit is going, we would go extinct.
Rather convenient that science only matters when the left decides it does.
When I "entered" fandom, back in the early '90s, fic was mostly in fanzine form still, but migrating to the 'net via MUDs and newsgroups and mailing lists.
Here's the thing though, most fic, regardless of source or fandom, was sorted into one of three categories: Gen, Het, and Slash.
Gen had no romantic pairings, but might focus on a character or two. Those characters would be listed with commas. (Kirk, Spock, McCoy)
Het was, as implied, heteroromantic and/or heterosexual and the pairings were represented by an ampersand. (Spock & Uhura, Kirk & Chapel)
Slash was not het or gen. Pairings were represented by a slash symbol; hence the name. (Kirk/Spock or Kirk/Spock/McCoy)
I lost track of the fandom communities for a bit in the late 00s/early 10s, discovering that LiveJournal had died, but AO3 was born (🎉🎉🎉) during my hiatus.
I was very confused by the change in the common useage of the & and / symbols, though I rather like the new system because it allows for a greater romantic diversity.
I learned, but I know there are older stories who's writers are no longer around who used the older system.
I also still see folks choosing all the tags for their pairings... possibly because it's not well explained anywhere or there are confusing descriptions depending on where you look?
Anyhoo... something to keep in mind. Or maybe I'm misremembering and should just go back to my corner. 😋
FOR IMMEDIATE RELEASE – October 31, 2025 AUSTIN, TX – Otsuka ICU Medical LLC is issuing a voluntary recall to the user level, for a MISLABEL
"Company Announcement
FOR IMMEDIATE RELEASE – October 31, 2025 AUSTIN, TX – Otsuka ICU Medical LLC is issuing a voluntary recall to the user level, for a MISLABELLED lot of POTASSIUM CHLORIDE Inj. 20 mEq, NDC 0990-7077-14. The OVERWRAP label of lot 1030613, Expiration Date: 09-30-2026 may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq with NDC 0990-7074-26. Otsuka ICU Medical LLC has identified this discrepancy due to a manufacturing issue. The dosage is correctly printed on the labeling affixed to the product bag which is not visible when the 10 mEq OVERWRAP is in place. This notification details the issue and the required steps for you to perform.
If the incorrect dosage on the 10 mEq overwrap is used instead of the correct 20mEq dosage printed on the product, an overdose of potassium chloride is possible. Overdose of potassium chloride can lead to hyperkalemia. Hazards of severe hyperkalemia after large intravenous overdoses causes neuromuscular dysfunction including muscle weakness, ascending paralysis, listlessness, vertigo, mental confusion, hypotension, cardiac dysrhythmias, or death from cardiac arrest. Premature infants, patients on chronic parenteral nutrition, patients who have a history of cardiac arrythmias, patients with chronic renal insufficiency, patients who have acute renal failure, patients on potassium-sparing diuretics—all are at risk for adverse and potentially fatal outcomes. Otsuka ICU Medical LLC has not received reports of adverse events associated with this issue to date.
INDICATIONS AND USAGE:
Potassium Chloride Injection 20 mEq and 10 mEq, is indicated in the treatment of potassium deficiency states, when oral replacement is not feasible.
THIS HIGHLY CONCENTRATED, READY-TO-USE POTASSIUM CHLORIDE INJECTION IS INTENDED FOR THE MAINTENANCE OF SERUM K+ LEVELS AND FOR POTASSIUM SUPPLEMENTATION IN FLUID RESTRICTED PATIENTS WHO CANNOT ACCOMMODATE ADDITIONAL VOLUMES OF FLUID ASSOCIATED WITH POTASSIUM SOLUTIONS OF LOWER CONCENTRATION. TO AVOID POTASSIUM INTOXICATION, DO NOT INFUSE THESE SOLUTIONS RAPIDLY.
When using these products, these patients should be on continuous cardiac monitoring and frequent testing for serum potassium concentration and acid-base balance.
The affected product lot was manufactured on 15 April 2025 and distributed in the United States between 23 May 2025 through 26 August 2025. The affected product lot (Located on the top left of the product bag or the case label is:
NDC Number: 0990-7077-14
List Number: 070770452
Product Description: POTASSIUM CHLORIDE Inj. 20 mEq
Lot Number: 103061330
Expiration Date: September 2026
Configuration: 50mL in Flexible Container
NDC Number: 0990-7074-26
List Number: 070740452
Product Description: POTASSIUM CHLORIDE Inj. 10 mEq
Lot Number: N/A
Expiration Date: N/A
Configuration: 100mL in Flexible Container
DESCRIPTION OF CASES BEING RECALLED:
NDC Number: 0990-7077-14
Barcode Number: (01)20309907077141
Lot Number: 1030613
Expiration Date: 30 September 2026
Configuration: 24/case
Overwrap Label Examples: See [link]
Overwrap and Product Image Mislabeled Example: See [link]
Otsuka ICU Medical LLC is notifying its customers, including distributors, of this recall by letter and is arranging for the return of all recalled products. All Customers, including distributors, that have product that is being recalled should stop use/further distribution, as applicable, and return to place of purchase.
To return affected product or if you require assistance, please contact Sedgwick at 1-888-566-2363 (M-F, 8am to 5pm ET) to obtain a return label.
For further inquiries, please contact Otsuka ICU Medical LLC using the information provided [at the link]."
Contact information for company available at the link, as are product photos.
08/27/2025– East Brunswick, NJ, Unichem Pharmaceuticals (USA), Inc. is voluntarily recalling one (1) lot of Cyclobenzaprine Hydrochloride Ta
"FOR IMMEDIATE RELEASE – 08/27/2025– East Brunswick, NJ, Unichem Pharmaceuticals (USA), Inc. is voluntarily recalling one (1) lot of Cyclobenzaprine Hydrochloride Tablets USP 10 mg, to the consumer level. The Cyclobenzaprine 10mg (90ct) label was inadvertently placed on a bottle containing Meloxicam 7.5 mg tablets.
Risk Statement: For patients who unknowingly take Meloxicam there is a reasonable probability of serious adverse events including cardiovascular, gastrointestinal, renal, anaphylaxis, and skin reactions, particularly in those patients taking concomitant non-steroidal anti-Inflammatory drugs and/or blood thinners, those who have allergies to the Meloxicam, or those with underlying illness. To date, Unichem Pharmaceuticals has not received any reports of adverse events related to this recall.
Meloxicam Tablets USP, 7.5 mg is a non-steroidal anti-inflammatory drug, indicated for use in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Rheumatoid Arthritis. Meloxicam Tablets, USP, 7.5 mg is light yellow, round flat beveled edged, tablet with “U & L” debossed on one side and “7.5” debossed centrally on the other side.
Cyclobenzaprine Hydrochloride Tablets USP, 10mg is a muscle relaxer and indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Cyclobenzaprine Hydrochloride Tablets, USP, 10 mg, are blue colored, film coated, round shaped, biconvex tablets, debossed with “U” on one side and “12” debossed on other side.
The mislabeled bottles of Cyclobenzaprine Hydrochloride Tablets USP, 10mg but containing Meloxicam 7.5mg tablets, can be identified by the lot number GMML24026A and expiry of Sept 2027 and NDC 29300-415-19 printed on the label of the 90-count bottles.
The product was distributed Nationwide to distributors, and further downstream distribution occurred to retailers and subsequently consumers.
Unichem Pharmaceuticals (USA), Inc. is notifying its downstream trading partners, their retailers and consumers of the recall through our third party recall provider, Inmar. Inmar is arranging for the return of the subject recalled Cyclobenzaprine Hydrochloride Tablets USP, 10mg labeled with Lot # GMML24026A. Our downstream trading partners that have Cyclobenzaprine Hydrochloride Tablets USP, 10mg with Lot# GMML24026A, Exp Sept 2027, which is being recalled, should not further distribute, this medication, and notify their customers accordingly. Retail pharmacies should not dispense from this lot number, GMML24026A, and call the number provided for guidance on how to return this drug product. Any pharmacy who has dispensed this lot of Cyclobenzaprine, should notify the consumer. Consumers should return the medication to the pharmacy they received their prescription from.
Consumers with questions regarding this recall can Inmar at 1-877-840-5109 or via email a to [email protected]; Monday – Friday (9 am – 5 pm; CST). Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.
Complete and submit the report online: www.fda.gov/medwatch/report.htm
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration."
The U.S. Food & Drug Administration (FDA) has announced a recall for select cans of zero-sugar 7Up soda because they may unintentionally contain full-sugar soda instead. More than 1,950 cases of 7Up Zero Sugar Tropical Soda have been recalled due to this labeling error.
The soda was initially recalled on July 31 by its manufacturer, Buffalo Rock Company Inc. The FDA classified the recall as…
Mondelez recollects some Ritz cracker sandwich cartons over mislabeling
Take a look at what’s clicking on FoxBusiness.com.
Mondelez International is recalling some cartons of Ritz cracker sandwiches over inaccurate labeling that would put individuals allergic to peanuts in danger.
The recall, introduced Tuesday, facilities on eight-pack, 20-pack and 40-pack cartons of Ritz peanut butter cracker sandwiches and 20-pack cartons of Ritz cracker sandwich selection…
